Besides Danaher's life science companies such as Pall, Aldevron, and Cytiva, other consortium members include the U.S. Food and Drug Administration, the National Institutes of Health, 12 pharmaceutical and biotech companies, and nine nonprofits. The Foundation for the National Institutes of Health manages the consortium as part of the Accelerating Medicines Partnership program.

The BGTC was formed in October 2021 in response to shortcomings in the current drug development model that makes it difficult for companies to recover the costs required to develop gene therapies to treat rare and ultra-rare diseases, Danaher said.

Cytiva, Pall to invest $1.5B in biomanufacturing over next 2 years
Cytiva and Pall, both Danaher companies, will make major investments in manufacturing capacity and services at 13 sites around the globe supporting life...